We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Protagonist Therapeutics Inc | NASDAQ:PTGX | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -1.20 | -3.76% | 30.74 | 29.22 | 45.00 | 32.14 | 30.64 | 31.87 | 441,376 | 05:00:03 |
From May 2019 to May 2024
NEWARK, Calif., Nov. 13, 2019 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer, will present at two upcoming healthcare investor conferences in New York.
Presentation details:
Event: Stifel 2019 Healthcare Conference
Date: Wednesday, Nov. 20
Time: 2:25 p.m. EST
Event: Piper Jaffray 31st Annual Healthcare Conference
Date: Thursday, Dec. 5
Time: 1:30 p.m. EST
Live and archived audio webcasts of the Stifel and Piper presentations can be accessed by visiting the Investors page of the Protagonist Therapeutics website at http://investors.protagonist-inc.com/.
About Protagonist Therapeutics, Inc.
Protagonist Therapeutics is a clinical stage biopharmaceutical company that utilizes a proprietary technology platform to discover and develop novel peptide-based drugs to transform existing treatment paradigms for patients with significant unmet medical needs. PTG-300 is an injectable hepcidin mimetic in development for the potential treatment of iron overload anemia and related rare blood diseases including beta-thalassemia and polycythemia vera. PTG-200 is an oral, gut-restricted interleukin-23 receptor specific antagonist peptide in Phase 2 clinical development for the potential treatment of inflammatory bowel disease, with Crohn's disease as the initial indication. The Company has a worldwide license and collaboration agreement with Janssen Biotech for the clinical development of PTG-200. PN-943 is an oral, gut-restricted alpha-4-beta-7 integrin specific antagonist peptide in clinical development for the potential treatment of inflammatory bowel disease, with a Phase 2 ulcerative colitis study expected to commence in the first half of 2020.
Protagonist is headquartered in Newark, California. For further information, please visit http://www.protagonist-inc.com.
View original content:http://www.prnewswire.com/news-releases/protagonist-therapeutics-to-present-at-two-upcoming-healthcare-investor-conferences-300957130.html
SOURCE Protagonist Therapeutics, Inc.
Copyright 2019 PR Newswire
1 Year Protagonist Therapeutics Chart |
1 Month Protagonist Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
